GH
Guardant Health, Inc.
Overview
Guardant Health provides blood and tissue tests that analyze cancer-related genetic and epigenomic changes to help oncologists select treatments, detect residual disease in early-stage cancer patients, and screen for cancer in asymptomatic individuals.
Guardant Health, Inc is a Healthcare company operating in Diagnostics & Research with a $17.08B market cap.
GH beat consensus EPS by 0.0% in Q1 FY2026, reported May 7, 2026.
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-0714 Q&A exchanges
- Q4 FY2025Earnings2026-02-1916 Q&A exchanges
- Q3 FY2025Earnings2025-10-3014 Q&A exchanges
- Q2 FY2025Earnings2025-07-3113 Q&A exchanges
- Q1 FY2025Earnings2025-04-3024 Q&A exchanges
- Q4 FY2024Earnings2025-02-2014 Q&A exchanges
- Q3 FY2024Earnings2024-11-0611 Q&A exchanges
- Q2 FY2024Earnings2024-08-0715 Q&A exchanges
- Q1 FY2024Earnings2024-05-0810 Q&A exchanges
- Q4 FY2023Earnings2024-02-2212 Q&A exchanges
- Q3 FY2023Earnings2023-11-0620 Q&A exchanges
- Q2 FY2023Earnings2023-08-0326 Q&A exchanges
- Q1 FY2023Earnings2023-05-0921 Q&A exchanges
- Q4 FY2022Earnings2023-02-2324 Q&A exchanges
- Q3 FY2022Earnings2022-11-0331 Q&A exchanges
- Q2 FY2022Earnings2022-08-0433 Q&A exchanges
- Q1 FY2022Earnings2022-05-0520 Q&A exchanges
- Q4 FY2021Earnings2022-02-2325 Q&A exchanges
- Q3 FY2021Earnings2021-11-0430 Q&A exchanges
- Q2 FY2021Earnings2021-08-0623 Q&A exchanges
- Q1 FY2021Earnings2021-05-06
History
Earnings history
- Q1 FY20262026-05-07EPS$-0.45 vs $-0.47+5.0%Rev$301.7M vs ——EODHD
- Q4 FY20252026-02-18EPS$-0.50 vs $-0.78+35.5%Rev$281.3M vs ——EODHD
- Q3 FY20252025-10-28EPS$-0.39 vs $-0.79+50.6%Rev$265.2M vs ——EODHD
- Q2 FY20252025-07-29EPS$-0.44 vs $-0.72+38.9%Rev$232.1M vs ——EODHD
- Q1 FY20252025-06-11EPS$-0.49 vs $-0.85+42.4%Rev$203.5M vs ——EODHD
- Q4 FY20242025-02-19EPS$-0.62 vs $-0.50-23.1%Rev$201.8M vs ——EODHD
- Q3 FY20242024-11-05EPS$-0.88 vs $-0.74-18.9%Rev$191.5M vs ——EODHD
- Q2 FY20242024-08-06EPS$-0.84 vs $-0.74-13.5%Rev$177.2M vs ——EODHD
- Q1 FY20242024-05-08EPS$-0.94 vs $-0.85-10.6%Rev$168.5M vs ——EODHD
- Q4 FY20232024-02-21EPS$-0.85 vs $-0.86+1.2%Rev$155.1M vs ——EODHD
- Q3 FY20232023-11-05EPS$-0.73 vs $-0.95+23.2%Rev$143.0M vs ——EODHD
- Q2 FY20232023-08-02EPS$-0.67 vs $-1.18+43.2%Rev$137.2M vs ——EODHD
- Q1 FY20232023-05-08EPS$-1.30 vs $-1.32+1.5%Rev$128.7M vs ——EODHD
- Q4 FY20222023-02-22EPS$-1.36 vs $-1.37+0.7%Rev$126.9M vs ——EODHD
- Q3 FY20222022-11-02EPS$-1.41 vs $-1.26-11.9%Rev$117.4M vs ——EODHD
- Q2 FY20222022-08-03EPS$-1.27 vs $-1.21-5.0%Rev$109.1M vs ——EODHD
- Q1 FY20222022-05-04EPS$-1.21 vs $-1.210.0%Rev$96.1M vs ——EODHD
- Q4 FY20212022-02-22EPS$-0.89 vs $-1.15+22.6%Rev$108.1M vs ——EODHD
- Q3 FY20212021-11-03EPS$-1.06 vs $-0.97-9.3%Rev$94.8M vs ——EODHD
- Q2 FY20212021-08-04EPS$-0.96 vs $-0.85-12.9%Rev$92.1M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-07 | $-0.45 | $-0.47 | +5.0% | $301.7M | — | — | EODHD |
| Q4 FY2025 | 2026-02-18 | $-0.50 | $-0.78 | +35.5% | $281.3M | — | — | EODHD |
| Q3 FY2025 | 2025-10-28 | $-0.39 | $-0.79 | +50.6% | $265.2M | — | — | EODHD |
| Q2 FY2025 | 2025-07-29 | $-0.44 | $-0.72 | +38.9% | $232.1M | — | — | EODHD |
| Q1 FY2025 | 2025-06-11 | $-0.49 | $-0.85 | +42.4% | $203.5M | — | — | EODHD |
| Q4 FY2024 | 2025-02-19 | $-0.62 | $-0.50 | -23.1% | $201.8M | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $-0.88 | $-0.74 | -18.9% | $191.5M | — | — | EODHD |
| Q2 FY2024 | 2024-08-06 | $-0.84 | $-0.74 | -13.5% | $177.2M | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-0.94 | $-0.85 | -10.6% | $168.5M | — | — | EODHD |
| Q4 FY2023 | 2024-02-21 | $-0.85 | $-0.86 | +1.2% | $155.1M | — | — | EODHD |
| Q3 FY2023 | 2023-11-05 | $-0.73 | $-0.95 | +23.2% | $143.0M | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $-0.67 | $-1.18 | +43.2% | $137.2M | — | — | EODHD |
| Q1 FY2023 | 2023-05-08 | $-1.30 | $-1.32 | +1.5% | $128.7M | — | — | EODHD |
| Q4 FY2022 | 2023-02-22 | $-1.36 | $-1.37 | +0.7% | $126.9M | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $-1.41 | $-1.26 | -11.9% | $117.4M | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $-1.27 | $-1.21 | -5.0% | $109.1M | — | — | EODHD |
| Q1 FY2022 | 2022-05-04 | $-1.21 | $-1.21 | 0.0% | $96.1M | — | — | EODHD |
| Q4 FY2021 | 2022-02-22 | $-0.89 | $-1.15 | +22.6% | $108.1M | — | — | EODHD |
| Q3 FY2021 | 2021-11-03 | $-1.06 | $-0.97 | -9.3% | $94.8M | — | — | EODHD |
| Q2 FY2021 | 2021-08-04 | $-0.96 | $-0.85 | -12.9% | $92.1M | — | — | EODHD |
Source: EODHD. GH reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks GH's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 6/10 quarters with 60% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Missed in 2 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $4.17 | $4.35 | -4.2% | -2.1% | -5.1% |
| Q4 FY2026 | $4.55 | $4.54 | +0.2% | +6.6% | +9.3% |
| Q3 FY2026 | $4.14 | $4.28 | -3.2% | +5.5% | +2.8% |
| Q2 FY2026 | $4.55 | $4.39 | +3.6% | +4.0% | +1.8% |
| Q1 FY2025 | $4.97 | $4.55 | +9.3% | +3.9% | +4.7% |
| Q4 FY2025 | $4.85 | $4.62 | +4.9% | +1.5% | -1.0% |
| Q3 FY2025 | $4.51 | $4.58 | -1.5% | 0.0% | -0.6% |
| Q2 FY2025 | $4.64 | $4.63 | +0.2% | +9.0% | +12.0% |
| Q1 FY2024 | $4.58 | $4.62 | -0.9% | -0.2% | +0.9% |
| Q4 FY2024 | $4.63 | $4.45 | +4.1% | -2.1% | -3.3% |
Guidance change history
Sample- Q1 FY2026Lowered2026-04-15
- Q4 FY2026Suspended2026-13-15
- Q3 FY2026Suspended2026-10-15
- Q2 FY2026Maintained2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Maintained2025-10-15
- Q2 FY2025Maintained2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Helmy EltoukhyCEO5 mo20 callsCurrentSample
CEO since 2026 • 1/2 beats (50%) • last guidance cut Q3 FY2026
- Amirali TalasazCEO5 mo20 callsCurrentSample
CEO since 2026 • 1/2 beats (50%) • guidance suspended Q3 FY2026
- Michael Brian BellCFO3 mono recorded callsCurrentSample
CFO since 2026 • 1/2 beats (50%) • guidance suspended Q1 FY2026
- Craig EagleChief Medical Officer3 mo1 callCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • last guidance cut Q1 FY2026
- Terilyn J MonroeChief People Officer3 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 2/2 beats (100%) • last guidance cut Q2 FY2026
- Chris FreemanChief Commercial Officer3 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 2/2 beats (100%) • last call held guidance Q1 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for GH.
$ curl https://api.spokenalpha.com/v1/companies/GHFAQ
Frequently asked about GH
Where can I find Guardant Health, Inc.'s (GH) earnings call transcripts?
Spoken Alpha indexes GH's earnings call transcripts at https://spokenalpha.com/companies/GH. Each call links to attributed speakers and parsed analyst Q&A. Guardant Health, Inc.'s own investor relations page is at https://investors.guardanthealth.com/overview/default.aspx.
When was Guardant Health, Inc.'s most recent earnings call?
Guardant Health, Inc. (GH) held its most recent earnings call on 2026-05-07, covering fiscal Q1 2026.
What sector is GH in?
Guardant Health, Inc. (GH) operates in the Healthcare sector (Diagnostics & Research industry).